TY - JOUR
T1 - Trailblazing precision medicine in Europe
T2 - A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany
AU - Stenzinger, Albrecht
AU - Edsjö, Anders
AU - Ploeger, Carolin
AU - Friedman, Mikaela
AU - Fröhling, Stefan
AU - Wirta, Valtteri
AU - Seufferlein, Thomas
AU - Botling, Johan
AU - Duyster, Justus
AU - Akhras, Michael
AU - Thimme, Robert
AU - Fioretos, Thoas
AU - Bitzer, Michael
AU - Cavelier, Lucia
AU - Schirmacher, Peter
AU - Malek, Nisar
AU - Rosenquist, Richard
AU - Lindstrand, Anna
AU - Wedell, Anna
AU - Gisselsson, David
AU - Melén, Erik
AU - Helenius, Gisela
AU - Ehrencrona, Hans
AU - Engstrand, Lars
AU - Palmqvist, Lars
AU - Levin, Lars Åke
AU - Lovmar, Lovisa
AU - Landström, Maréne
AU - Hallbeck, Martin
AU - Wadelius, Mia
AU - Sikora, Per
AU - Beer, Ambros J.
AU - Illert, Anna L.
AU - Budczies, Jan
AU - Nikolaou, Konstantin
AU - Kohlbacher, Oliver
AU - Horak, Peter
AU - Kuhn, Peter
AU - Schroeder, Christopher
AU - Boerries, Melanie
AU - Lassmann, Silke
AU - Gaidzik, Verena I.
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2022/9
Y1 - 2022/9
N2 - Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to precision medicine to patients independent of their place of residence. Two of these multicentric initiatives, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) initiative in Germany have teamed up to present and share their views on core concepts, potentials, challenges, and future developments in precision medicine. Together with other initiatives worldwide, GMS and ZPM aim at providing a robust and sustainable framework, covering all components from technology development to clinical trials, ethical and legal aspects as well as involvement of all relevant stakeholders, including patients and policymakers in the field.
AB - Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to precision medicine to patients independent of their place of residence. Two of these multicentric initiatives, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) initiative in Germany have teamed up to present and share their views on core concepts, potentials, challenges, and future developments in precision medicine. Together with other initiatives worldwide, GMS and ZPM aim at providing a robust and sustainable framework, covering all components from technology development to clinical trials, ethical and legal aspects as well as involvement of all relevant stakeholders, including patients and policymakers in the field.
KW - Cancer
KW - Clinical trials
KW - Molecular profiling
KW - Personalized medicine
KW - Precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85111382323&partnerID=8YFLogxK
U2 - 10.1016/j.semcancer.2021.05.026
DO - 10.1016/j.semcancer.2021.05.026
M3 - Review article
C2 - 34033893
AN - SCOPUS:85111382323
SN - 1044-579X
VL - 84
SP - 242
EP - 254
JO - Seminars in Cancer Biology
JF - Seminars in Cancer Biology
ER -